Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01373125 · ClinicalTrials.gov registry record
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
A clinical trial of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD), sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 99
- Enrollment target
- 1
- Study location
NCT01373125: Completed study of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD), sponsored by University of North Carolina, Chapel Hill.
NCT01373125 is a study of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD) that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 99 participants, below the 520-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01373125, a study of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD), has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a study comparing the morphological and functional aspects of the neosquamous epithelium (NSE) after ablative therapy for dysplastic Barrett's esophagus (BE) to that of native squamous epithelium in normal controls as well as gastroesophageal reflux disease (GERD), non-Barrett's Esophagus (BE) subjects.
Primary Outcome
To characterize reflux symptomatology before and after radiofrequency ablation in subjects with dysplastic BE. We will compare before and after gastroesophageal reflux disease (GERD) symptom assessment scale (GSAS) symptom scores using paired Student's t tests. As an exploratory analysis, we will further stratify the data by PPI use (once- vs. twice-daily.
Conditions Studied
Study Locations (1)
North Carolina
- University of North Carolina Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-10 |
What the finished NCT01373125 record still lists
NCT01373125 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 520-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Barrett's Esophagus appearing as the primary indexed condition, and to 0 interventions.
NCT01373125 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01373125 about?
NCT01373125 is a clinical study titled "Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?". The investigators propose a study comparing the morphological and functional aspects of the neosquamous epithelium (NSE) after ablative therapy for dysplastic Barrett's esophagus (BE) to that of native squamous epithelium in normal controls as well as gastroesophageal reflux disease (GERD), non-Barr...
What is the current status of trial NCT01373125?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2011-06. Estimated completion is 2014-10.
What conditions does trial NCT01373125 study?
This clinical trial studies the following conditions: Barrett's Esophagus, Gastroesophageal Reflux Disease (GERD), Intestinal Metaplasia.
Who is sponsoring clinical trial NCT01373125?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01373125 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barrett's Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01373125's enrollment target sits among peer trials
99 10th of 22 higher than 13 of 22 other Barrett's Esophagus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Barrett's Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System
RECRUITING · NA
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Barrett's Esophagus Related Neoplasia (BERN) Project
RECRUITING
-
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING
-
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
RECRUITING
-
Navicam for Detection of Barrett's Esophagus
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia